Is PRECIGEN, INC. (PGEN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.5% / 30% | 8.3% / 30% | 0.1% / 30% | 36.13% / 5% | ✗ NOT HALAL |
| DJIM | 0.5% / 33% | 8.3% / 33% | 0.1% / 33% | 36.13% / 5% | ✗ NOT HALAL |
| MSCI | 3.8% / 33% | 67.4% / 33% | 0.8% / 33% | 36.13% / 5% | ✗ NOT HALAL |
| S&P | 0.5% / 33% | 8.3% / 33% | 0.1% / 33% | 36.13% / 5% | ✗ NOT HALAL |
| FTSE | 3.8% / 33% | 67.4% / 33% | 0.8% / 50% | 36.13% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -474.6% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -572.0% | |
| Return on Assets (ROA) | -44.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$68M |
| Free Cash Flow | -$77M |
| Total Debt | $6M |
| Debt-to-Equity | 470.0 |
| Current Ratio | 3.1 |
| Total Assets | $145M |
Price & Trading
| Last Close | $3.90 |
| 50-Day MA | $4.07 |
| 200-Day MA | $3.45 |
| Avg Volume | 4.0M |
| Beta | 1.2 |
|
52-Week Range
$1.11
| |
About PRECIGEN, INC. (PGEN)
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PRECIGEN, INC. (PGEN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PRECIGEN, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PRECIGEN, INC.'s debt ratio?
PRECIGEN, INC.'s debt ratio is 0.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.8%.
What are PRECIGEN, INC.'s key financial metrics?
PRECIGEN, INC. has a market capitalization of $1.3B, and revenue of $4M. Return on equity stands at -572.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.